News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
175,185 Results
Type
Article (7830)
Company Profile (22)
Press Release (167332)
Multimedia
Podcasts (15)
Webinars (2)
Section
Business (55957)
Career Advice (354)
Deals (9863)
Drug Delivery (26)
Drug Development (22409)
Employer Resources (32)
FDA (3669)
Job Trends (3952)
News (89045)
Policy (6349)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Premier (1)
Academia (510)
Accelerated approval (14)
Adcomms (8)
Allergies (52)
Alliances (5807)
ALS (58)
Alzheimer's disease (434)
Antibody-drug conjugate (ADC) (160)
Approvals (3923)
Artificial intelligence (99)
Autoimmune disease (106)
Automation (11)
Bankruptcy (70)
Best Places to Work (3550)
BIOSECURE Act (4)
Biosimilars (57)
Biotechnology (16)
Bladder cancer (101)
Brain cancer (27)
Breast cancer (346)
Cancer (2332)
Cardiovascular disease (226)
Career advice (294)
Career pathing (3)
CAR-T (89)
CDC (9)
Celiac Disease (1)
Cell therapy (261)
Cervical cancer (22)
Clinical research (21064)
Collaboration (343)
Company closure (2)
Compensation (208)
Complete response letters (17)
COVID-19 (582)
CRISPR (73)
C-suite (114)
Cystic fibrosis (33)
Data (3569)
Depression (48)
Dermatology (46)
Diabetes (210)
Diagnostics (1684)
Digital health (11)
Diversity (3)
Diversity, equity & inclusion (12)
Drug discovery (63)
Drug pricing (27)
Drug shortages (4)
Duchenne muscular dystrophy (82)
Earnings (48338)
Editorial (14)
Employer branding (5)
Employer resources (26)
Events (35516)
Executive appointments (90)
FDA (4900)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (5)
Frontotemporal dementia (15)
Funding (276)
Gene editing (138)
Generative AI (6)
Gene therapy (244)
GLP-1 (378)
Government (937)
Grass and pollen (1)
Guidances (340)
Healthcare (4847)
HIV (30)
Huntington's disease (21)
IgA nephropathy (55)
Immunology and inflammation (89)
Immuno-oncology (35)
Indications (72)
Infectious disease (682)
Inflammatory bowel disease (64)
Inflation Reduction Act (2)
Influenza (42)
Intellectual property (46)
Interviews (69)
IPO (6178)
IRA (8)
Job creations (584)
Job search strategy (255)
JPM (7)
Kidney cancer (13)
Labor market (28)
Layoffs (166)
Leadership (4)
Legal (1183)
Liver cancer (34)
Longevity (3)
Lung cancer (350)
Lymphoma (233)
Machine learning (13)
Management (10)
Manufacturing (154)
MASH (85)
Medical device (3283)
Medtech (3319)
Mergers & acquisitions (4030)
Metabolic disorders (574)
mRNA (39)
Multiple sclerosis (77)
NASH (9)
Neurodegenerative disease (106)
Neuropsychiatric disorders (34)
Neuroscience (894)
NextGen: Class of 2026 (1325)
Non-profit (872)
Now hiring (16)
Obesity (273)
Opinion (46)
Ovarian cancer (74)
Pain (57)
Pancreatic cancer (101)
Parkinson's disease (109)
Partnered (5)
Patents (99)
Patient recruitment (141)
Peanut (16)
People (5245)
Pharmaceutical (5)
Pharmacy benefit managers (7)
Phase 1 (5500)
Phase 2 (8786)
Phase 3 (8574)
Pipeline (4322)
Policy (42)
Postmarket research (848)
Preclinical (1922)
Press Release (16)
Prostate cancer (105)
Psychedelics (13)
Radiopharmaceuticals (97)
Rare diseases (335)
Real estate (652)
Recruiting (8)
Regulatory (5625)
Reports (17)
Research institute (428)
Resumes & cover letters (52)
Rett syndrome (31)
RNA editing (6)
RSV (32)
Schizophrenia (63)
Series A (37)
Series B (24)
Sickle cell disease (57)
Special edition (9)
Spinal muscular atrophy (41)
Sponsored (9)
Startups (529)
State (1)
Stomach cancer (7)
Supply chain (24)
Tariffs (13)
The Weekly (15)
Vaccines (277)
Venture capital (21)
Weight loss (212)
Women's health (41)
Worklife (5)
Date
Today (80)
Last 7 days (259)
Last 30 days (1268)
Last 365 days (9982)
2026 (4490)
2025 (10060)
2024 (11375)
2023 (12820)
2022 (15347)
2021 (15098)
2020 (13776)
2019 (10991)
2018 (8211)
2017 (8221)
2016 (7144)
2015 (8990)
2014 (6199)
2013 (4618)
2012 (5210)
2011 (5393)
2010 (4871)
Location
Africa (150)
Alabama (26)
Alaska (1)
Arizona (73)
Arkansas (1)
Asia (10833)
Australia (1566)
California (4268)
Canada (1186)
China (538)
Colorado (209)
Connecticut (170)
Delaware (189)
Europe (24425)
Florida (540)
Georgia (160)
Hawaii (1)
Idaho (8)
Illinois (317)
India (27)
Indiana (268)
Iowa (3)
Japan (220)
Kansas (39)
Kentucky (13)
Louisiana (19)
Maine (51)
Maryland (439)
Massachusetts (3133)
Michigan (78)
Minnesota (191)
Missouri (43)
Montana (8)
Nebraska (2)
Nevada (38)
New Hampshire (19)
New Jersey (1429)
New Mexico (1)
New York (1108)
North Carolina (485)
North Dakota (2)
Northern California (2279)
Ohio (102)
Oklahoma (5)
Oregon (3)
Pennsylvania (911)
Puerto Rico (6)
Rhode Island (7)
South America (251)
South Carolina (9)
Southern California (1624)
Tennessee (37)
Texas (659)
United States (15061)
Utah (108)
Virginia (56)
Washington D.C. (15)
Washington State (326)
West Virginia (1)
Wisconsin (32)
175,185 Results for "9".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Chiesi snaps up KalVista for $1.9B, betting big on rare disease med Ekterly
Chiesi Group is taking KalVista Pharmaceuticals under its wing, paying $1.9 billion for the biotech’s oral therapy Ekterly to treat severe swelling episodes caused by the rare genetic disorder hereditary angioedema.
April 29, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
A single dose of Lilly’s PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
May 25, 2026
·
8 min read
Job Trends
9 Companies Hiring in Boston
Looking for a biopharma job in Boston? Check out the
BioSpace
list of nine companies hiring life sciences professionals like you.
February 11, 2026
·
1 min read
·
Angela Gabriel
Pancreatic cancer
ASCO: Biopharma has pancreatic cancer ‘surrounded’ as Immuneering’s drug adds 9 quality months
In addition to eliciting 17.3 months median overall survival vs. 8.5 months for patients given standard of care treatment in a prior study, Immuneering’s atebimetinib demonstrated a robust tolerability profile—something CEO Ben Zeskind said equates highly with survival.
June 1, 2026
·
4 min read
·
Heather McKenzie
Job Trends
9 Companies Hiring Now in Pennsylvania
Looking for a biopharma job in Pennsylvania? Check out the
BioSpace
list of nine companies hiring life sciences professionals like you.
February 19, 2026
·
2 min read
·
Angela Gabriel
Press Releases
Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026
April 13, 2026
·
3 min read
Press Releases
World’s First | Mabwell’s 9MW5211 Receives FDA Clearance for Clinical Trial Application
May 10, 2026
·
5 min read
Press Releases
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
May 27, 2026
·
9 min read
Press Releases
ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO
June 1, 2026
·
4 min read
Press Releases
Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader
April 2, 2026
·
2 min read
1 of 17,519
Next
